F-STAR THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • March 31st, 2021 • F-Star Therapeutics, Inc. • Pharmaceutical preparations • New York
F-star Therapeutics, Inc. (formerly known as Spring Bank Pharmaceuticals, Inc. (“Spring Bank”)), a Delaware corporation (the “Company”, with all references in this agreement to the “Company” also referring to Spring Bank prior to the date on which, pursuant to the terms of the Exchange Agreement, dated as of July 29, 2020, among Spring Bank, F-star Therapeutics Limited (“Former F-star”) and the sellers listed on Schedule I thereto, the shareholders of Former F-star exchanged all of their ordinary shares for shares of common stock of Spring Bank, resulting in Former F-star becoming a wholly-owned subsidiary of Spring Bank; and in connection therewith, Spring Bank changed its name to F-star Therapeutics, Inc.), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
